Gilead brings in Michael Quigley as SVP of research biology, he joins the company from Bristol-Myers Squibb. In his previous company, Quigley had been VP and head of tumor microenvironment modulation thematic research center.
In this former position, he had been responsible for dictating strategy within BMS’ oncology discovery program – identifying targets and developing both small and large molecule therapeutics.
Before his position with BMS Quigley also held roles at Janssen, as a senior scientific director, and at MedImmune, working as a scientist within the company’s preclinical oncology department.
At the same time as Gilead made the appointment of Quigley public, the biotech also announced that Linda Higgins had been promoted from within to SVP and head of external innovation.
Both employees will report to William Lee, EVP of Research at Gilead.
“We are very pleased to welcome Quigley to Gilead and Higgins to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented Dr. Lee. “These appointments strengthen our research discovery organization and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”